847675-82-5

Basic information

• Product Name: 2-bis(tert-butoxycarbonyl)amino-4,6-dichloropyrimidine
• Synonyms: 2-bis(tert-butoxycarbonyl)amino-4,6-dichloropyrimidine
• CAS NO: 847675-82-5
• Molecular Formula: C14H19Cl2N3O4
• Molecular Weight: 364
• Mol File: 847675-82-5.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-bis(tert-butoxycarbonyl)amino-4,6-dichloropyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bis(tert-butoxycarbonyl)amino-4,6-dichloropyrimidine(847675-82-5)
• EPA Substance Registry System: 2-bis(tert-butoxycarbonyl)amino-4,6-dichloropyrimidine(847675-82-5)

Safety Data

• Hazardous Substances Data: 847675-82-5(Hazardous Substances Data)

Upstream product

• 56-05-3 2-Amino-4,6-dichloropyrimidine 
• 24424-99-5 di-tert-butyl dicarbonate 

Relevant articles and documents

Hierarchical self-assembly of a bow-shaped molecule bearing self-complementary hydrogen bonding sites into extended supramolecular assemblies

The bow-shaped molecule 1 bearing a self-complementary DAAD-ADDA (D = donor A = acceptor) hydrogen-bonding array generates, in hydrocarbon solvents, highly ordered supramolecular sheet aggregates that subsequently give rise to gels by formation of an entangled network. The process of hierarchical self-assembly of compound 1 was investigated by the concentration and temperature dependence of UV-visible and 1H NMR spectra, fluorescence spectra, and electron microscopy data. The temperature dependence of the UV-visible spectra indicates a highly cooperative process for the self-assembly of compound 1 in decaline. The electron micrograph of the decaline solution of compound 1 (1.0 mM) revealed supramolecular sheet aggregates forming an entangled network. The selected area electronic diffraction patterns of the supramolecular sheet aggregates were typical for single crystals, indicative of a highly ordered assembly. The results exemplify the generation, by hierarchical self-assembly, of highly organized supramolecular materials presenting novel collective properties at each level of organization.

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS

Compound (I), deuterated derivatives, and pharmaceutically acceptable salts of any of the foregoing are disclosed. Methods of treating cystic fibrosis using these compounds are also disclosed.